Description: Protecting underserved communities from diseaseInnovating with pragmatic creativity to develop affordable, effective, and accessible vaccines and immunotherapies against infectious disease and cancer. AAHI and Afrigen Biologics Expand Partnership on Vaccine Adjuvants for Essential Life Saving Vaccines for Africa and to Contribute to the Continent’s Pandemic Preparedness and Health SecurityAugust 1, 2024 PRIORITIZING ACCESSA practical approach to
About Us Our Story Our Impact Tuberculosis Neglected Tropical Diseases Snake Bite Envenomation Amebiasis Malaria Leadership DEI Products and Services Adjuvant Formulations Platform RNA Platform Product Development and Characterization Manufacturing & Supply Next Generation Solutions Media Scientific Publications Newsletter Careers Contact Our Mission We build platforms for
We look forward to sharing our immune-enhancing platforms and deep formulation expertise at the World Vaccine Congress next week in Washington D.C. We would be delighted to meet with you – connect with us directly or visit booth #805 to learn more about how AAHI scientists are developing products that enable accessible and equitable health solutions for people who most need them.
AAHI’s novel temperature-stable single-vial adjuvant-containing tuberculsosis vaccine candidate (ID93+GLA-SE) is safe and elicits a stronger immune response in humans than administration of the non-thermostable presentation ID93+GLA-SE. The temperature-stable vaccine candidate can be stored for several months at nearly 100 degrees Fahrenheit.